Drug Makers Moving Back into Antibiotic R&D

The Wall Street Journal reported that drug companies are getting back into the hunt for antibiotics.
As quoted in the market news:

Pharmaceutical companies moved out of antibiotic development en masse in the past 15 years, citing high research costs, poor returns and onerous regulations. Consequently, the pipeline for new antibiotics dried up. In the 1980s, 30 new antibiotics gained approval in the U.S. Between 2010 and 2012, only one did.

Read the full article on Wall Street Journal